The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (UMEC/VI) is an approved combination therapy for on...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Multidiscip Respir Med
Auteurs principaux: Buikema, Ami R., Brekke, Lee, Anderson, Amy, Koep, Eleena, Van Voorhis, Damon, Sharpsten, Lucie, Hahn, Beth, Ray, Riju, Stanford, Richard H.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Original Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180385/
https://ncbi.nlm.nih.gov/pubmed/30338068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0151-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires